Brief: Lumos Pharma To Present New Data On Three PGHD Patients Treated With Lum-201 In Prior Phase 2 Study
27/04/2021 13:21
April 27 (Reuters) - Lumos Pharma Inc LUMO.O :
* NEWLY RELEASED DATA ON THREE PGHD PATIENTS TREATED WITH
LUM-201
IN PRIOR PHASE 2 STUDY TO BE PRESENTED IN LUMOS PHARMA KEY
OPINION LEADER WEBINAR
Source text for Eikon: ID:nGNX1qdF9G
Further company coverage: LUMO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lumos Pharma
See all newsLumos Pharma Inc expected to post a loss of 76 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Apple, Hershey, Dow
U.S. STOCKS ON THE MOVE-Magnite, Nvidia, Tesla
Lumos Pharma climbs on $38 mln go-private deal
Brief: Lumos Pharma Enters Into Definitive Merger Agreement With Double Point Ventures To Go Private Via A Tender Offer Of $4.25 Cash Per Share Plus Contingent Value Rights (Cvr)